Provenance Specimen

GLP-1 receptor agonist (public encyclopedia provenance reconstruction)

Reconstructed from 22 public encyclopedia revisions showing article evolution

Illustrative

POSITION Provenance reconstruction

CONTEXT Metabolic

UPDATED Phase 1 · automated · public encyclopedia revision history

Source

22 revisions 3 claim families 14 variants 9 events

Reproducibility

Independent assertion extraction and claim-family grouping by two analysts, with disagreements resolved by documented criteria.

3/3 Family overlap

11/14 Variant overlap

1 Documented disagreement

Passed Reproducibility gate

Documented disagreement

Disagreement: Bridge process split a drug-list assertion into two families because word overlap fell below the 0.5 threshold; human analyst treated it as one semantic family.

Resolution: Added section-anchored joining: merge assertions in the same section when overlap > 0.3.

Re-review trigger

Review recommended

Evidence movement detected relative to stated reliance. Review when practical.

Evidence trajectory is moderate based on 3 claim families and 3 assessments.
Reliance scope is strong from 1 endorsement(s) and 2 operational-use commitment(s).
Feasibility signals are strong from assertion scan for restrictions and approvals.

Assessments

Family	Direction	Variants	Disputes	Last change	Basis
fam-sentence-1	disputed	3	1	2012-08-22	analyst asserted
fam-sentence-2	mixed	7	0	2012-09-27	analyst asserted
fam-sentence-3	mixed	4	0	2012-09-27	analyst asserted

Claim Families

One of their advantages is that they have a lower risk of ca... 3 variants · 2 relationships

var-fam-sentence-1-1

One of their advantages is that they have a lower risk of causing hypoglycemia

Seen: 2009-01-13 · Basis: normalized

var-fam-sentence-1-2

One of their advantages (over insulin?) is that they have a lower risk of causing hypoglycemia

Seen: 2010-07-27 · Basis: normalized

var-fam-sentence-1-3

One of their advantages over older insulin secretagogues, such as sulfonylureas or meglitinides, is that they have a lower risk of causing hypoglycemia

Seen: 2012-08-22 · Basis: normalized

Relationships

qualifies var-fam-sentence-1-1 → var-fam-sentence-1-2

qualifies var-fam-sentence-1-2 → var-fam-sentence-1-3

Licenced : exenatide (2005) Under investigation : liragluti... 7 variants · 6 relationships

var-fam-sentence-2-1

Licenced : exenatide (2005) Under investigation : liraglutide, albiglutide, taspoglutide ==References==

Seen: 2009-01-13 · Basis: normalized

var-fam-sentence-2-2

Licenced : exenatide Under investigation : liraglutide, albiglutide ==References==

Seen: 2009-01-13 · Basis: normalized

var-fam-sentence-2-3

Licenced : exenatide (2005) Under investigation : albiglutide, taspoglutide ==References==

Seen: 2010-01-26 · Basis: normalized

var-fam-sentence-2-4

Licenced : exenatide (2005), liraglutide (2010) Under investigation : albiglutide, taspoglutide ==References==

Seen: 2010-01-27 · Basis: normalized

var-fam-sentence-2-5

Licenced : exenatide (2005), liraglutide (2010) Under investigation : albiglutide, taspoglutide, AVE0010

Seen: 2010-07-27 · Basis: normalized

var-fam-sentence-2-6

Licensed GLP-1 agonists: exenatide (licensed 2005), liraglutide (licensed 2010) Under investigation: albiglutide, taspoglutide, AVE0010

Seen: 2012-08-17 · Basis: normalized

var-fam-sentence-2-7

Licensed GLP-1 agonists: * exenatide (Byetta), licensed in 2005 * liraglutide (Victoza), licensed 2010 Under investigation: albiglutide, taspoglutide, AVE0010

Seen: 2012-09-27 · Basis: normalized

Relationships

narrows var-fam-sentence-2-1 → var-fam-sentence-2-2

qualifies var-fam-sentence-2-2 → var-fam-sentence-2-3

qualifies var-fam-sentence-2-3 → var-fam-sentence-2-4

qualifies var-fam-sentence-2-4 → var-fam-sentence-2-5

qualifies var-fam-sentence-2-5 → var-fam-sentence-2-6

qualifies var-fam-sentence-2-6 → var-fam-sentence-2-7

Glucagon-like peptide-1 agonists (GLP-1 agonists) are new cl... 4 variants · 3 relationships

var-fam-sentence-3-1

Glucagon-like peptide-1 agonists (GLP-1 agonists) are new classes of drugs for the treatment of type 2 diabetes

Seen: 2012-08-17 · Basis: normalized

var-fam-sentence-3-2

Glucagon-like peptide-1 analogs are a new class of drug for treatment of type 2 diabetes

Seen: 2012-08-17 · Basis: normalized

var-fam-sentence-3-3

Glucagon-like peptide-1 agonists (GLP-1 agonists) are a new class of drug for the treatment of type 2 diabetes

Seen: 2012-08-17 · Basis: normalized

var-fam-sentence-3-4

Glucagon-like peptide-1 agonists (GLP-1 agonists) are a class of drugs for the treatment of type 2 diabetes

Seen: 2012-09-27 · Basis: normalized

Relationships

narrows var-fam-sentence-3-1 → var-fam-sentence-3-2

qualifies var-fam-sentence-3-2 → var-fam-sentence-3-3

qualifies var-fam-sentence-3-3 → var-fam-sentence-3-4

Events

2012-01-30 Revert detected Reverted edits by [[Special:Contributions/59.95.72.254|59.95.72.254]] ([[User talk:59.95.72.254|talk]]) to last revision

2023-11-12 Page moved: GLP-1 receptor agonist → Draft:Move/Glucagon-like peptide-1 receptor agonist from=GLP-1 receptor agonist to=Draft:Move/Glucagon-like peptide-1 receptor agonist comment=[[WP:PMRC#4|Round-robin histo

2012-08-17 Talk page correlation time_delta_hours=0 talk_comment=Facts707 moved page [[Talk:Glucagon-like peptide-1 analog]] to [[Talk:Glucagon-like pept

2012-08-17 Talk page correlation time_delta_hours=129.3 talk_comment=Facts707 moved page [[Talk:Glucagon-like peptide-1 analog]] to [[Talk:Glucagon-like

2005-04-28 FDA approves exenatide for type 2 diabetes FDA approves exenatide (Byetta), the first GLP-1 receptor agonist, for type 2 diabetes treatment.

2010-01-25 FDA approves liraglutide for type 2 diabetes FDA approves liraglutide (Victoza), expanding the GLP-1 receptor agonist class for type 2 diabetes.

2024-01-01 ADA Standards of Care endorse GLP-1 receptor agonists American Diabetes Association Standards of Care recommend GLP-1 receptor agonists for type 2 diabetes, particularly in p

Review Decisions

reject Confident

Family: fam-sentence-1 · Trigger: Revert detected

Reverted edits by [[Special:Contributions/59.95.72.254|59.95.72.254]] ([[User talk:59.95.72.254|talk]]) to last revision by PhiLiP ([[WP:HG|HG]])

adopt Confident

Family: fam-sentence-3 · Trigger: FDA approves exenatide for type 2 diabetes · Impact: support-enhanced

FDA approval provides direct institutional operationalization of the class-level T2D claim.

amend Confident

Family: fam-sentence-2 · Trigger: FDA approves liraglutide for type 2 diabetes · Impact: support-enhanced

Add liraglutide to the list of licensed GLP-1 agonists without changing the family scope.

retain-with-caveats Uncertain

Family: fam-sentence-3 · Trigger: ADA Standards of Care endorse GLP-1 receptor agonists · Impact: support-enhanced

Endorsement supports the class claim but is inferred from guideline language, not an operational record; retain with ASCVD qualification.

Institutional Reliance

FDA operational-use high

Exenatide (Byetta) approval for type 2 diabetes, NDA 021773

on var-fam-sentence-3-3

FDA approval converts the evidence claim "GLP-1 agonists are a class of drugs for type 2 diabetes" into an operational regulatory commitment for exenatide.

2005-04-28 · Basis: institution confirmed

FDA operational-use high

Liraglutide (Victoza) approval for type 2 diabetes, NDA 022341

on var-fam-sentence-2-6

FDA approval extends the operational commitment to another GLP-1 agonist, supporting the family that exenatide and liraglutide are licensed options.

2010-01-25 · Basis: institution confirmed

American Diabetes Association endorsement medium

Standards of Care in Diabetes — Glycemic Goals and Telehealth

on var-fam-sentence-3-3

ADA Standards of Care endorse GLP-1 receptor agonists for type 2 diabetes, particularly when atherosclerotic cardiovascular disease is present. This is an endorsement inferred from guideline language, not an operational record of a specific institution acting on it.

2024-01-01 · Basis: inferred

Source Citations

www.fda.gov http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/uc 2010-01-27

www.medscape.com Glucagon-like Peptide-1 Analogs Other Than Exenatide 2010-07-27

www.fda.gov FDA Approves New Treatment for Type 2 Diabetes 2010-07-27

www.medscape.com http://www.medscape.com/viewarticle/578304 2010-07-27

www.fda.gov http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/uc 2010-07-27

www.medscape.com http://www.medscape.com/viewarticle/578304 2010-07-27

www.fda.gov http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/uc 2010-07-27

www.medscape.com Glucagon-like Peptide-1 Analogs Other Than Exenatide 2010-07-27

www.fda.gov FDA Approves New Treatment for Type 2 Diabetes 2010-07-27

Unknown Unnamed citation 2012-08-22

Cross-specimen impact propagation

Changes in related specimens can affect this claim history. These links are the seed of monitoring: they show where an event in one domain should trigger reconsideration in another.

← Incoming support-enhanced high

From: Liraglutide (public encyclopedia provenance reconstruction) · family fam-sentence-7

FDA approval of liraglutide for chronic weight management strengthens the cross-specimen claim that GLP-1-class drugs, including liraglutide, have an obesity/weight-management indication.

Triggered by event: FDA approves liraglutide for chronic weight management

→ Outgoing support-enhanced medium

To: Liraglutide (public encyclopedia provenance reconstruction) · family fam-sentence-3

The GLP-1 class ADA endorsement supports the liraglutide T2D mechanism claim because liraglutide is a member of the endorsed class.

Triggered by event: ADA Standards of Care endorse GLP-1 receptor agonists

What this specimen demonstrates

This public example shows a capability NextConsensus can deploy now: reconstructing how a medical claim changed across source versions, grouping related statements into claim families, surfacing where the record was disputed or weakened, linking claims to evidence of institutional reliance, and propagating impacts across related specimens.

The underlying method preserves source-addressable artifacts, extracted assertions, claim identity, reviewer-attributed state, reliance inferences, and cross-specimen impact links. The specimen is illustrative; it is not a recommendation for clinical or institutional action.

Classification

Evidentiary

public encyclopedia version identifiers
Edit timestamps
Editor usernames
Edit comments
Citation URLs
Page move records
Template changes

Derived

Sentence-level diffs (before/after)
Citation added/removed events
Section reorganization events
Edit magnitude (minor/moderate/major)
Content change type
Key terms extraction
Direction signal (strengthening/weakening/neutral)

Inferred

Claim family membership
Claim variant relationships
Confidence assignment
Impact direction
Decision rationale reconstruction
Reliance commitment interpretation